Symbio Life Sciences is the manifestation of a long-held vision of Dr. Dennis McKenna. Symbio connects conscious investors with innovative life science ventures that can elevate and positively impact humanity.
Symbio provides the support necessary to take a project from the “idea state” to a commercially viable company. Our thorough and well managed process is designed to efficiently utilize investor resources while maximizing impact.
Symbio is attracting a collective of like-minded investors who have awakened to the simple fact that the best hope for humanity is a shift in consciousness. The heart and soul of Symbio is matching up investor resources with the ideas that matter most– ideas that can have a global impact on the greater good of mankind. Collectively WE can make a difference.
There are thousands of ideas competing for attention at any given time. At Symbio, our vetting process ensures that only those ideas that successfully meet our criteria for a mission aligned venture will be added to the Symbio portfolio:
Nurturing a vetted idea as it grows into a self sustaining company/enterprise requires skillful attention. Symbio takes a team approach with each enterprise to ensure it has the best opportunity for success. From science and Strategy to management and marketing, each subsidiary has the full support of experts in a variety of domains.
Our focus is on medicinal plants, novel nutrition, ecological innovations and mind/body integrations. We are committed to bringing these new ideas and companies to the world with the highest level of integrity and respect.
The current renaissance with medicinal plants has created a deep interest in the therapeutic applications of these powerful and often transformational allies. Our interest is grounded in breakthrough approaches for developing, producing and distributing of these alternative solutions for global health.
A new dawn is calling us forward into a greater understanding and appreciation for the nutrition that can be provided by our planet. We are interested in discovering and developing unique, nutrient dense foods that can help bring about optimal health and wellness in our global population.
There is a major shift occurring across the globe that is causing us to recognize the necessity of aligning with our planet in a way that sustains all life. Our ecological interest rests firmly in ideas that both utilize and replenish the abundant resources readily available in order to reorient the trajectory of humanity’s future.
The emerging field of consciousness is demonstrating the significance of the mind/body connection as a means of understanding our own existence. We want to help foster this movement with tools to support new levels of connectivity and a heightened awareness of who we are becoming.
Radical Medicinals, LLC is a company that is developing a new and natural methodology to produce Clinical grade compounds from plant sources. It’s first target compound is Ibogaine, a valuable alkaloid found in the roots of a West African shrub.
• Has been shown to interrupt opiate dependence and other forms of chemical imbalance.
• Shows promise as a treatment for Parkinson’s Disease and other neurological ailments.
• Global demand for Ibogaine is causing an ecological disaster for this plant in its natural habitat.
Our technology allows us to produce the plant and its compounds in a way that:
• Shortens the production cycle from 7 years down to 1 month
• Minimizes the ecological pressure from overharvesting the plant in its natural environment
• Conserves the plant in its culture of origin so traditional ritual use can continue
Dr. Eduardo Jovel
University of British Columbia
Chief Science Officer | Radical Medicinals
Dr. Dennis McKenna received his doctorate from the University of British Columbia in Vancouver and is currently Assistant Professor in the Center for Spirituality and Healing at the University of Minnesota. He is a consultant to several companies doing research in plant medicine. He has conducted extensive ethnobotanical fieldwork in the Peruvian, Colombian, and Brazilian Amazon and has recently completed a four-year project investigating Amazonian ethno medicines as potential treatments for cognitive disorders in schizophrenia. Dr. McKenna completed post-doctoral fellowship research and has held the following professional positions:
Dr. McKenna is also author or co-author of several books and over 40 scientific papers published in peer-reviewed journals. He is well respected among his peers and maintains a reputation as a pioneer among entheogen and plant medicine scholars.
At Symbio we are fortunate to be surrounded by a community of accomplished and well seasoned experts in a variety of fields. Whether it is plant science and business science, or investments and finance to product development, within our network we have a deep bench to pull from when we find gaps that cannot be filled by our small and agile start-up team